Meeting
2021 ASCO Annual Meeting
Palbociclib (P) in patients (pts) with head and neck cancer (HNC) with CDKN2A loss or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Presenter
Evan P. Pisick, MD
Cancer Treatment Centers of America
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02693535
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6043)
DOI
10.1200/JCO.2021.39.15_suppl.6043
Abstract #
6043
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Gastrointestinal Cancers Symposium
Abemaciclib in patients (pts) with esophageal cancer (EC) with CDKN2A loss or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Speaker: Vi Kien Chiu, PhD
Videos & Slides
2021 ASCO Annual Meeting
Palbociclib (P) in patients (pts) with soft tissue sarcoma (STS) with CDK4 amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Speaker: Scott Schuetze, MD, PhD
Videos & Slides
2024 ASCO Gastrointestinal Cancers Symposium
Talazoparib (Tala) in patients (pts) with colorectal cancer (CRC) with BRCA1/2 mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Speaker: Timothy Lewis Cannon, MD
Videos & Slides
2023 ASCO Annual Meeting
Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Speaker: Inderjit Mehmi, MD